GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

February 13, 2027

Study Completion Date

September 10, 2027

Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
DRUG

GC012F injection

"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment,the infusion doses will be (CAR-T cell count) 3 × 10\^5/kg.~Note: for subjects weighing ≤70 kg: number of infused CAR-T cells = 3 (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CART cells (fixed doses of GC012F Injection) = 3 (±20%) × 10\^5 × 70 kg."

Trial Locations (1)

430000

RECRUITING

Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY

lead

Daishi Tian

OTHER